Behçet's disease

Arthritis Research and Therapy

Volumn 5, Issue 3, 2003, Pages 139-146

  Hirohata, Shunsei ^a   Kikuchi, Hirotoshi ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HLA B51; Neutrophil; T lymphocytes; Treatment; Tumor necrosis factor alpha

Indexed keywords

ALPHA2A INTERFERON; COLCHICINE; CYCLOSPORIN A; ETANERCEPT; HLA B51 ANTIGEN; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

APHTHOUS STOMATITIS; BEHCET DISEASE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; GENETIC SUSCEPTIBILITY; GENITAL ULCER; HUMAN; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROTOXICITY; REVIEW; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; UVEITIS;

ANIMALS; BEHCET SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HLA-B ANTIGENS; HUMANS;

EID: 0038300754     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M: Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982, 100:1455-1458.
2. Mizuki N, Ohno S, Sato T, Ishihara M, Miyata S, Nakamura S, Naruse T, Mizuki H, Tsuji K, Inoko H: Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behcet's disease. Hum Immunol 1995, 43:129-135.
3. Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Shiina T, Nomura E, Onari K, Ohno S, Inoko H: HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behcet's disease. Tissue Antigens 2001, 58:181-184.
4. Ota M, Mizuki N, Katsuyama Y, Tamiya G, Shiina T, Oka A, Ando H, Kimura M, Goto K, Ohno S, Inoko H: The critical region for Behcet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet 1999, 64:1406-1410.
5. Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, Nakamura S, Bahram S, Ohno S, Inoko H: Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 1999, 42:1961-1966.
6. Cohen R, Metzger S, Nahir M, Chajek-Shaul T: Association of the MIC-A gene and HLA-B51 with Behcet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann Rheum Dis 2002, 61: 157-160.
7. Sano K, Yabuki K, Imagawa Y, Shiina T, Mizuki N, Ohno S, Kulski JK, Inoko H: The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet's disease. Tissue Antigens 2001, 58:77-82.
8. Kera J, Mizuki N, Ota M, Katsuyama Y, Pivetti-Pezzi P, Ohno S, Inoko H: Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behcet's disease in Italian patients. Tissue Antigens 1999, 54:565-571.
9. Gül A, Hajeer AH, Worthington J, Barrett JH, Ollier WE, Silman AJ: Evidence for linkage of the HLA-B locus in Behcet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001, 44:239-241.
10. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408
11. Malfroy L, Roth MP, Carrington M, Borot N, Volz A, Ziegler A, Coppin H: Heterogeneity in rates of recombination in the 6-Mb region telomeric to the human major histocompatibility complex. Genomics 1997, 43:226-231.
12. Gül A, Hajeer AH, Worthington J, Ollier WE, Silman AJ: Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum 2001, 44:2693-2696.
13. Touitou I, Magne X, Molinari N, Navarro A, Quellec AL, Picco, P, Seri M, Ozen S, Bakkaloglu A, Karaduman A, Garnier JM, Demaille J, Kone-Paut I: MEFV mutations in Behcet's disease. Hum Mutat 2000, 16:271-272.
14. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990, 63:1099-1112.
15. Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T: Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995, 38:426-433.
16. Ergun T, Gurbuz O, Harvell J, Jorizzo J, White W: The histopathology of pathergy: a chronologic study of skin hyper-reactivity in Behcet's disease. Int J Dermatol 1998, 37:929-933.
17. Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P: Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 1995, 132:901-907.
18. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989, i:1093-1096.
19. The Behcet's Disease Research Committee of Japan: Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease - a multicenter study. J Rheumatol 1989, 16:506-511.
20. Hirohata S, Oka H, Mizushima Y: Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992, 140:410-419.
21. Pervin K, Childerstone A, Shinnick T, Mizushima Y, van der Zee R, Hasan A, Vaughan R, Lehner T: T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol 1993, 151:2273-2282.
22. Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, van der Zee R, Stanford MR, Sanderson J, Lehner T: Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease. Lancet 1996, 347:789-794.
23. Freysdottir J, Lau S, Fortune F: Gammadelta T cells in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999, 118:451-457.
24. Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS: Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol 2002, 130:46-54.
25. De Libero G: Sentinel function of broadly reactive human gamma delta T cells. Immunol Today 1997, 18:22-26.
26. Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, Kogure M, Inaba G, Sakane T: Role of gammadelta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol 1997, 107:241-247.
27. Schondelmaier S, Wesch D, Pechhold K, Kabelitz D: V gamma gene usage in peripheral blood gamma delta T cells. Immunol Lett 1993, 38:121-126.
28. Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T: Oligoclonal T cell expansions in patients with Behcet's disease. Clin Exp Immunol 1999, 117:166-170.
29. Esin S, Gul A, Hodara V, Jeddi-Tehrani M, Dilsen N, Konice M, Andersson R, Wigzell H: Peripheral blood T cell expansions in patients with Behcet's disease. Clin Exp Immunol 1997, 107: 520-527.
30. Hirohata S, Hashimoto T: Abnormal T cell responses to bacterial superantigens in Behcet's disease (BD). Clin Exp Immunol 1998, 112:317-324.
31. Frassanito MA, Dammacco R, Cafforio P, Dammacco F: Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999, 42:1967-1974.
32. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K: Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002, 31: 205-210.
33. Mantas C, Direskeneli H, Oz D, Yavuz S, Akoglu T: IL-8 producing cells in patients with Behcet's disease. Clin Exp Rheumatol 2000, 18:249-251.
34. Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, Yamamoto S, Sakane T: Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan. Clin Exp Immunol 1997, 108:204-212.
35. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM, Frei U, Jorres A: IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000, 165:5814-5821.
36. Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T: Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999, 162:4328-4335.
37. Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloum M, Ben Ahmed M, Miled M: Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol 2001, 19(suppl 24):S48-S50.
38. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002, 112:37-43.
39. Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E: Enhancement of endothelial cell E-selection expression by sera from patients with active Behcet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999, 91:330-337.
40. Kobayashi M, Ito M, Nakagawa A, Matsushita M, Nishikimi N, Sakurai T, Nimura Y: Neutrophil and endothelial cell activation in the vase vasorum in vasculo-Behcet disease. Histopathology 2000, 36:362-371.
41. Serdaroglu P: Behçet's disease and the nervous system. J Neurol 1998, 245:197-205.
42. Kidd D, Steuer A, Denman AM, Rudge P: Neurological complications in Behcet's syndrome. Brain 1999, 122:2183-2194.
43. Kawai M, Hirohata S: Cerebrospinal fluid beta(2)-microglobulin in neuro-Behcet's syndrome. J Neurol Sci 2000, 179:132-139.
44. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H: Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999, 106:586-589.
45. Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T: Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997, 82:12-17.
46. Hirohata S, Suda H, Hashimoto T: Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998, 159:181-185.
47. Matsumura N, Mizushima Y: Leucocyte movement and colchicine treatment in Behcet's disease [letter]. Lancet 1975, 2:813.
48. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H: A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001, 44:2686-2692.
49. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E: Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467-471.
50. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:443-450.
51. Kari JA, Shah V, Dillon MJ: Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 2001, 40:933-938.
52. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996, 35: 969-979.
53. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
54. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky PE: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
55. Robertson LP, Hickling P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford) 2001, 40:473-474.
56. Goossens PH, Verburg RJ, Breedveld FC: Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy [concise report]. Ann Rheum Dis 2001, 60:637.
57. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001, 120:995-999.
58. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296.
59. Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, Akbarian M, Gharibdoust F: High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short term results of 23 patients. Book of Abstracts. 10th International Conference on Behçet's Disease; Berlin. June 27-29, 2002:69.